Our studies with an orally bioavailable ABn regimen (metformin+navitoclax) consistently demonstrated therapeutic potential and efficacy in different models of MYC-overexpressing breast cancer, including TNBC cell lines, breast cancer explants, the WapMyc mouse model of breast adenocarcinoma, and patient-derived xenografts. Here, MYC is linked to breast cancer.